Equinix Inc vs Hinge Health Inc. Class A Common Stock — how do they compare? Equinix Inc trades at $995.9 (market cap $100.59B), while Hinge Health Inc. Class A Common Stock trades at $104.95 (market cap $8.48B). The key difference: Equinix Inc is far larger — about 11.9× Hinge Health Inc. Class A Common Stock's market cap, and Equinix Inc pays a 2.02% dividend while Hinge Health Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Equinix Inc for 110 Days and Hinge Health Inc. Class A Common Stock for 0 Days on average.
| EQIX | HNGE | |
|---|---|---|
Market Cap | $100.59B | $8.48B |
Volume | 409,185 | 879,799 |
Sector | Real Estate | Health |
52-Week High | $1.12K | $105.14 |
52-Week Low | $726.09 | $31.17 |
Typical Hold Time | 110 Days | 0 Days |
Enterprise Value | $121.72B | $8.10B |
Dividend Yield | 2.02% | — |
Signals from Pluang's Aura AI — not financial advice
Equinix (EQIX) trades at $995.9, down 3.55% today, amid mixed technical signals but strong analyst support. The stock shows bullish moving averages and neutral oscillators, with key support at $1,008. Fundamentally, revenue grew to $9.22B in 2025 with a net income margin of 15.63%, though valuation ratios remain elevated with a P/E of 65.6. Recent news highlights AI-driven data center demand and a $5B-$7B annual expansion plan, positioning EQIX for growth despite recent earnings misses.
Outlook: EQIX benefits from robust AI and interconnection demand, with a consensus price target of $1,250 implying ~25% upside. Risks include high capital expenditures, debt levels rising to 47.13% of assets, and execution challenges in a competitive sector. The strong buy rating (75% of analysts) and dividend yield support a positive medium-term view, but investors should monitor capex efficiency and quarterly earnings consistency.
Hinge Health (HNGE) trades at $105.14, up 0.31% on the day and near its 52-week high. The stock shows strong analyst support with a 93.75% buy rating, though the current price exceeds the consensus target of $101.62. Recent earnings beat expectations in two of the last three quarters, with Q3 2026 results due November 2. Fundamentals indicate robust revenue growth projections from $588 million in 2025 to $720 million in 2026, alongside a shift to profitability, but valuation multiples like EV/EBITDA at 82.33 remain elevated.
The outlook is cautiously optimistic given projected profitability and expansion into migraine and GI care, but risks include high insider selling, competitive pressures, and the stock's premium valuation. Execution on growth targets and Q3 earnings will be critical for sustaining momentum.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Equinix is a retail provider of data centers, enabling hundreds of enterprise tenants to house their servers and networking equipment in a collocated environment. Tenants can then connect with each other, through cloud service providers and telecom networks. Equinix operates 240 data centers in 66 markets worldwide and owns just less than half of them. The firm has roughly 10,000 customers, including 2,000 networks, that are dispersed over five verticals: Cloud and IT Services, Content Providers, Network and Mobile Services, Financial Services, and Enterprise. About 70% of Equinix's revenue comes from renting space to tenants and related services, and more than 15% comes from connecting customers with each other. Equinix operates as a real estate investment trust.
Read more on EQIX →Hinge Health Inc. operates a digital musculoskeletal (MSK) care platform that delivers exercise therapy for joint and muscle conditions through health plans and employers. Its Precision Motion Technology combines wearable sensors and computer vision to guide patients through clinician-directed physical therapy remotely.
Read more on HNGE →